William Blair Has Optimistic Outlook of Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair lifted their Q2 2025 EPS estimates for Hologic in a research report issued to clients and investors on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will post earnings per share of $1.07 for the quarter, up from their previous estimate of $1.05. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 earnings per share.

A number of other equities analysts have also weighed in on HOLX. UBS Group upped their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Raymond James upped their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

Shares of HOLX stock opened at $79.18 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic has a 52 week low of $67.59 and a 52 week high of $84.67. The company’s 50 day moving average price is $80.84 and its two-hundred day moving average price is $78.22. The company has a market capitalization of $18.39 billion, a P/E ratio of 23.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in shares of Hologic during the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic during the third quarter valued at approximately $25,000. iA Global Asset Management Inc. bought a new stake in Hologic during the first quarter worth $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the 2nd quarter worth $37,000. Finally, First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.